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Until recently, methicillin-resistant Staphylococcus au-
reus (MRSA) has caused predominantly healthcare-asso-
ciated infections. We studied MRSA infections and overall 
skin and soft tissue infections (SSTIs) in outpatients receiv-
ing care at the Baltimore Veterans Affairs Medical Center 
Emergency Care Service during 2001–2005. We found an 
increase in MRSA infections, from 0.2 to 5.9 per 1,000 vis-
its (p<0.01); most were community-associated SSTIs. Mo-
lecular typing showed that >80% of MRSA infections were 
caused by USA300. In addition, SSTI visits increased from 
20 to 61 per 1,000 visits (p<0.01). The proportion of SSTI 
cultures that yielded MRSA increased from 4% to 42% 
(p<0.01), while the proportion that yielded methicillin-sensi-
tive S. aureus remained the same (10% to 13%, p = 0.5). 
The increase in community-associated MRSA infections 
and the overall increase in SSTIs in our population suggest 
that USA300 is becoming more virulent and has a greater 
propensity to cause SSTIs.
M
ethicillin-resistant  Staphylococcus aureus (MRSA) 
has been a cause of predominantly nosocomial or 
healthcare-associated infections. MRSA infections usually 
affect patients during hospitalization, after surgery, and dur-
ing stays in long-term care facilities. In addition, MRSA 
infections are common in patients who have indwelling 
vascular catheters for dialysis or other medical treatments. 
However, during the past decade, multiple reports of com-
munity-associated MRSA (CA-MRSA) infections have been 
reported in patients who lack the above risk factors (1–4).
CA-MRSA infections differ from healthcare-associ-
ated MRSA (HA-MRSA) infections in a number of ways. 
CA-MRSA infections are predominantly skin and soft 
tissue infections (SSTIs), are often susceptible to other 
non–β-lactam antimicrobial drugs, and carry a type IV or 
V staphylococcal cassette chromosome (SCC) with the 
mecA gene. In contrast, HA-MRSA infections are found 
at multiple sites, are usually multidrug resistant, and carry 
the SCCmec types I, II, and III (5,6). In the United States, 2 
major clones of CA-MRSA have been identiﬁ  ed by pulsed-
ﬁ  eld gel electrophoresis (PFGE) and named USA300 and 
USA400 by the Centers for Disease Control and Prevention 
(CDC) (7). Among the community-associated types, the 
USA300 clone has recently emerged as the predominant 
cause of SSTIs in the United States (8,9). Toxin expression 
between CA-MRSA and HA-MRSA strains differs. Most 
CA-MRSA strains carry the intracellular toxin Panton-Val-
entine leukocidin (PVL), which is known for pore formation 
on polymorphonuclear cells of the host (10,11). In addition, 
the USA300 clone contains the arginine catabolic mobile 
element (ACME), which inhibits polymorphonuclear cell 
production (10).
In the summer of 2004, physicians in our Emergency 
Care Service (ECS) alerted us to an increased number of 
outpatients who had SSTIs caused by MRSA. This obser-
vation led us to begin this investigation with the following 
objectives: 1) to measure the incidence of MRSA infec-
tions in our ECS, 2) to describe these infections and their 
isolates, and 3) to measure the incidence of SSTIs in our 
ECS and the entire associated healthcare system over the 
past 5 years. We present molecular and epidemiologic evi-
dence that the emergence of the USA300 clone has led to 
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not only an increase in CA-MRSA infections but also an 
overall increase in SSTIs in our patient population.
Methods
Setting
The population for our retrospective study was derived 
from the Veterans Affairs Maryland Health Care System 
(VAMHCS), which provides comprehensive health care 
to >45,000 veterans in the Maryland area. Outpatient care 
is provided at 2 medical centers and 3 community-based 
outpatient clinics. Our ECS is located in the Baltimore VA 
Medical Center and serves ≈85 patients a day.
MRSA Infections
We reviewed microbiology cultures obtained during 
an ECS visit from October 1, 2000, through September 30, 
2005 (ﬁ  scal years [FYs] 2001–2005), in which MRSA was 
ﬁ  rst isolated from a patient’s culture. The total number of 
ECS visits per FY was obtained from administrative re-
cords. The MRSA infection risk was calculated by divid-
ing the total number of ECS patients whose culture results 
were MRSA positive for the ﬁ  rst time by the number of 
ECS visits per FY. Information about patient demograph-
ics, clinical manifestations, and risk factors for nosocomial 
acquisition of MRSA was obtained from manual review of 
the VA’s computerized patient record system. Patients were 
categorized as to site of infection as follows: SSTI (wound 
culture positive for MRSA in the setting of new erythema, 
induration, warmth or pain at that site), urinary tract infec-
tion (positive urine culture in addition to at least 1 sign or 
symptom of a urinary tract infection), and pneumonia (posi-
tive sputum culture for MRSA in addition to a new inﬁ  ltrate 
on chest radiograph). The infection was classiﬁ  ed as health-
care-associated if the patient had a history of hospitalization, 
surgery, dialysis, or had been a resident in a long-term care 
facility within 1 year before infection or had a percutaneous 
medical device or permanent indwelling catheter at the time 
of infection. An infection in a patient without these risk fac-
tors was categorized as community-associated (12).
MRSA Isolates
Clinical cultures were sent to the clinical microbiology 
laboratory of the VAMHCS. S. aureus was identiﬁ  ed by fol-
lowing standard laboratory protocols. MRSA was deﬁ  ned 
as an S. aureus isolate that grew on oxacillin screen agar; 
methicillin-susceptible S. aureus (MSSA) was deﬁ  ned as 
an isolate that did not grow on oxacillin screen agar. Anti-
microbial drug susceptibility was determined by following 
the methods and interpretation guidelines of the Clinical 
and Laboratory Standards Institute (13). Erythromycin-re-
sistant and clindamycin-susceptible isolates were tested for 
inducible resistance by the D-test, following the guidelines 
that began on January 30, 2004. Clindamycin resistance 
data include all isolates that are truly resistant by break-
point and isolates that have inducible resistance detected 
by the D-test. All isolates were frozen at –70°C in trypti-
case soy broth with 30% glycerol. MRSA isolates (n = 329) 
were typed by DNA sequencing analysis of the protein A 
(spa) gene hypervariable region as described (14). Allele 
identiﬁ   cation was based on comparison with sequences 
in an S. aureus database (www.ridom.de/spaserver). PVL 
(15) and ACME (10) virulence factors were detected by 
following published protocols. PFGE was performed ac-
cording to McDougal et al. (7). Photographic images of 
the gels were saved digitally with the Geldoc EQ (BioRad 
Laboratories, Hercules, CA, USA); gel analysis was saved 
with Fingerprinting II Software (BioRad Laboratories). 
The reference standard S. aureus NCTC 8325 was included 
in the ﬁ  rst and ﬁ  fteenth lane of each gel, and all isolates 
were normalized to this global standard. The band patterns 
were compared by means of the Dice coefﬁ  cient by using 
the unweighted pair-group method to determine band simi-
larity and following the criteria established by Tenover et 
al. to deﬁ  ne the pulsed-ﬁ  eld type clusters (16). We deﬁ  ned 
USA300 as isolates that had the MBQBLO repeat motif 
and were positive for PVL and ACME.
SSTIs
For SSTIs, the total number of ECS visits (n = 3,688) 
and VAMHCS visits (n = 13,041) per FY, according to 
codes from the International Classiﬁ   cation of Disease, 
Clinical Modiﬁ  cation 9 (ICD-9-CM) (680, carbuncle and 
furuncle; 681, cellulitis and abscess of ﬁ  nger and toe; 682, 
other cellulitis and abscess; 704.8, folliculitis), were ob-
tained from administrative records. The rate of SSTIs was 
calculated for the ECS and the VAMHCS by dividing the 
number of total visits for SSTIs by the number of visits per 
FY for each site. We also measured the number of patients 
who had SSTIs by taking the ﬁ  rst patient visit for each year. 
Finally, we assessed whether patients’ infections were cul-
tured during their visits for SSTI and whether that culture 
grew MRSA or MSSA.
Statistical Analysis
Rates were computed as previously mentioned. Pro-
portions were used to describe categorical variables and 
means to describe continuous variables. Categorical vari-
ables were compared by using χ2 or Fisher exact tests, as 
appropriate; continuous variables were compared by using 
Student t test. Statistical analysis was performed by using 
SPSS version 12.5 (SPSS Inc., Chicago, IL, USA).
Results
The proportion of ECS visits for MRSA infections for 
patients with no history of MRSA colonization or infec-Skin and Soft Tissue Infections Caused by MRSA USA300
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tion increased signiﬁ  cantly from 0.2 per 1,000 ECS visits 
in FY01 to 5.9 per 1,000 visits in FY05 (p<0.01, χ2 test; 
Figure 1). The absolute number rose from 6 in FY01 to 
180 in FY05, and 280 (81%) of 329 cases occurred during 
FY04 and FY05. In FY01, only 3 SSTIs were caused by 
MRSA compared with 159 in FY05.
The mean age of patients with new MRSA infections 
(n = 329) was 56 years; 98% were male, 69% were African 
American, 84% had an SSTI, 8% had a urinary tract infec-
tion, 2% had pneumonia, and 6% had other sites of infec-
tion. Of these 329 MRSA isolates, 76% were susceptible 
to clindamycin, 85% to tetracycline (n = 257), and 97% to 
trimethoprim-sulfamethoxazole. Overall, 217 (66%) of the 
329 patients with MRSA infections had no known contact 
with the healthcare system in the year before their infection 
and most likely acquired MRSA in the community.
Molecular typing was performed on 296 (90%) of 
the 329 MRSA isolates from these infections. Spa typing 
showed a single dominant clonal type with the MBQBLO 
repeat motif (Table 1). The proportion of isolates tested 
with this spa type group signiﬁ  cantly increased from 0% in 
FY01 to 89% in FY05 (p<0.01, χ2 test). Isolates that con-
tained the virulence factors PVL and ACME also increased 
signiﬁ  cantly from 0% in FY01 to 93% in FY04 and 89% in 
FY05 (p<0.01, χ2 test) and strongly correlated with isolates 
of the MBQBLO repeat motif. Molecular studies showed 
that isolates deﬁ  ned as USA300 by having the MBQBLO 
repeat motif and being positive for PVL and ACME in-
creased from 0% in FY01 to 84% in FY05 and that USA300 
was the dominant clone in FY03–FY05.
To conﬁ  rm that isolates of the spa clonal type that had 
the MBQBLO repeat motif and were positive for ACME 
and PVL represent USA300, we performed PFGE on a 
subset of the isolates (n = 31). This subset consisted of a 
random selection of 10% of the total isolates. Sixteen iso-
lates were positive for USA300 by both typing methods: 
1) PFGE and 2) containing the MBQBLO repeat motif, 
PVL, and ACME. Three isolates had PFGE types similar 
to USA300 and PVL but had neither the MBQBLO repeat 
motif nor ACME. Twelve of the isolates did not have PFGE 
or spa types similar to USA300. No isolate was positive for 
MBQBLO repeat motif, PVL, and ACME and negative for 
USA300 by PFGE. When the MBQBLO that were ACME 
and PVL positive were compared with PFGE patterns for 
USA300, the sensitivity was 84% and the speciﬁ  city was 
100%; positive predicted value was 100% and negative 
predicted value was 80%.
Not all isolates that were USA300 according to PFGE 
correlated with the MBQBLO repeat motif and were posi-
tive for PVL and ACME. One isolate had an unrelated spa 
type (BQBPO repeat motif), and 2 isolates were negative 
for ACME. Eighteen of these isolates had the MBQBLO 
repeat motif, and PFGE showed a similarity to PFGE type 
USA300 (Figure 2). PFGE in our study determined that all 
of these related USA300 isolates carried PVL and all except 
2 carried the ACME virulence factor. The 2 without ACME 
were closely related to SCCmec IVb type. However, of the 
overall 329 MRSA isolates, 5 had the MBQBLO repeat 
motif and were PVL positive but ACME negative. Four 
isolates had the MBQBLO repeat motif (spa type t064) but 
Figure 1. Methicillin-resistant Staphylococcus aureus (MRSA) 
infections in patients without a history of MRSA per 1,000 visits 
to the Baltimore Veterans Affairs Medical Center Emergency Care 
Service (ECS), 2001–2005. SSTI, skin and soft tissue infection; FY, 
ﬁ  scal year. FY01–03 versus FY04, χ2 test, p<0.001.
Table 1. Molecular typing of isolates from patients with new MRSA infections, Baltimore Veterans Affairs Medical Center Emergency 
Care Service, 2001–2005*  
spa typing 
Time 
period
No.
isolates
tested
MBQBLO motif,† 
no. (%) 
MDMGMK motif,‡ 
no. (%) 
Other spa types,§ 
no. (%) 
PVL,
no. (%) 
ACME,
no. (%) 
MBQBLO motif, 
PVL, and ACME, 
no. (%) 
FY01 2 0 2  (100)  0 0 0 0
FY02  13 4 (31)  5 (38)  4 (31) 3 (23)  3 (23)  2 (17) 
FY03  21 15 (71)  6 (29)  0 15 (71)  15 (71)  15 (71) 
FY04  94 77 (82)  14 (15)  3 (3)  74 (80)  70 (75)  68 (74) 
FY05  166 147 (89)  15 (9)  4 (2)  154 (93)  147 (89)  138 (84) 
Total 296 243 (82)  42 (14)  11 (4)  246 (83)  235 (79)  223 (76) 
*MRSA, methicillin-resistant Staphylococcus aureus; PVL, Panton-Valentine leukocidin; ACME, arginine catabolic mobile element; FY, fiscal year. 
†spa types t008, t024, t112, t622, t064, t068, t121, t1881. 
‡spa types t002, t045, t242, t548, t539. 
§spa types t018, t019, t084, t128, t160, t216, t937, t1887. RESEARCH
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were negative for PVL and ACME and similar to USA500 
according to PFGE; these isolates were excluded from our 
deﬁ  nition of USA300.
Because most of these MRSA infections were SSTIs 
and because our ECS physicians thought they were seeing 
more abscesses, we looked at the rate of SSTIs in the ECS. 
The rate of ECS visits for SSTI signiﬁ  cantly increased from 
20 per 1,000 ECS visits in FY01 to 61 per 1,000 visits in 
FY05 (Figure 3). Because of concerns that some of the same 
patients had multiple visits, we looked at patients with SS-
TIs in each year. The results were similar to SSTI visits 
and showed an increase over the years in the number of 
patients with SSTIs (Table 2). The absolute number and the 
proportion of patients for whom culture was performed in-
creased from FY01–03 through FY04–05 (p<0001, χ2 test). 
We then examined the absolute number and the proportion 
of patients for whom cultures were performed and grew S. 
aureus (MRSA or MSSA). For our comparison of MRSA 
and MSSA, we chose this measurement to account for the 
increase in culturing. For MRSA, the absolute number and 
proportion of patients for whom cultures were performed 
and grew MRSA increased signiﬁ  cantly from FY01–03 
through FY04–05 (p<0001, χ2 test). For MSSA, the abso-
lute number of patients for whom cultures were performed 
and grew MSSA increased from FY01–03 through FY04–
05, but the proportion of patients for whom cultures were 
performed and grew MSSA remained the same (p = 0.10, 
χ2 test). Because of concerns that there may have been shifts 
in where care was delivered within our healthcare system, 
we also examined the number and rate of SSTIs for the en-
tire VAMHCS. Absolute numbers of visits increased, with 
2,020 visits in FY01, 1,972 in FY02, 2,190 in FY03, 3,337 
in FY04, and 3,522 in FY05. The rate of SSTI visits also 
increased (2.75 SSTI visits per 1,000 visits in FY01–03 vs. 
3.89 SSTI visits per 1,000 visits in FY04–05; p<0.001).
Discussion
During our 5-year study, we had an ≈4-fold increase 
in the incidence of MRSA infections, primarily SSTIs in 
people who had no risk factors for acquiring the infection 
from a healthcare setting. We showed that this increase was 
due to the USA300 clone and associated with an overall in-
crease in SSTIs in our ECS and in the healthcare system as 
a whole. For these patients with SSTIs, the absolute number 
and proportion of those for whom a culture was performed 
and grew MRSA increased. We believe this reﬂ  ects the in-
crease in MRSA infections due to USA300. The absolute 
number of patients for whom a culture was performed and 
grew MSSA also increased, but the proportion remained 
the same. We believe the absolute numbers increased be-
cause more cultures were performed, not because MSSA 
infections increased.
Other reports of community-onset MRSA infec-
tions throughout the United States have been published 
(5,8,17–19). A recent publication by King et al. showed 
that USA300 was the predominant cause of SSTIs in the 
community (8). Carlton et al. also documented an increase 
in the number of total MRSA infections in San Francisco 
during 1996–2002 (9). This increase was shown to coincide 
with a statistically signiﬁ  cant temporal increase in the num-
ber of community-onset MRSA infections. This study and 
our study support the hypothesis that CA-MRSA strains 
have factors that facilitate their spread in the community 
(18,20,21).
Despite the retrospective nature of our investigation, we 
were able to obtain 90% of the MRSA isolates for molecular 
typing. Molecular characterization of new cases of MRSA 
showed a dramatic increase in isolates with the MBQBLO 
repeat motif in the later years. This increase in these related 
spa types is consistent with the increase in the PFGE type 
USA300 seen by others (6,19). Not surprisingly, with the 
Figure 2. Pulsed-ﬁ   eld gel electrophoresis (PFGE) of a stratiﬁ  ed 
random sample of USA300 isolates and corresponding PCR results 
for Panton-Valentine leukocidin (PVL) and arginine catabolic mobile 
element (ACME). The Centers for Disease Control and Prevention’s 
PFGE results for USA300, USA300-0114, and SCCmec IVb were 
added as controls.
Figure 3. Visits for skin and soft tissue infections (SSTIs) in 
Baltimore Veterans Affairs Medical Center Emergency Care Service 
(ECS), 2001–2005. FY, ﬁ   scal year. FY01–03 versus FY04–05, 
χ2 test, p<0.001.Skin and Soft Tissue Infections Caused by MRSA USA300
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increase in the MBQBLO repeat motif, we also observed 
an increase in the virulence factors PVL and ACME. We 
did ﬁ  nd 4 isolates of the spa type 65 that were negative for 
PVL and ACME and were similar to USA500 by PFGE 
and 5 isolates that were spa type 8 and positive for PVL 
but negative for ACME. This ﬁ  nding was not surprising 
because this phenomenon has been recently described; only 
isolates with the SCC mec IVa harbored the ACME gene 
(22).
We noted that SSTIs more than doubled during the 5 
years of our investigation. The increase in SSTIs has also 
been observed throughout the United States. For example, 
a study by CDC showed that the visit rate for SSTIs during 
2001–2003 was 410.7 per 10,000 persons (23). Although 
an overall increase in SSTIs was not seen, SSTIs in the 
ECS increased by 59% and for hospital outpatient depart-
ment visits increased by 31%. These increases could be as-
sociated with the emergence of CA-MRSA infections and 
are consistent with our study ﬁ  ndings, which showed that 
this increase was due to the USA300 clone and also with an 
overall increase in SSTIs.
The potential limitations of this study include the study 
population and its retrospective nature. Because the study 
population consisted of veterans who received treatment 
through the VA Maryland Healthcare System, and thus 
were mainly male patients of low socioeconomic status, the 
study was not a true population-based study. Although we 
focused only on the veteran population, we believe that our 
ﬁ  ndings are consistent with those of other scientiﬁ  c stud-
ies and are relevant to most emergency department popula-
tions. The use of a veteran population is also an advantage. 
We were able to obtain more comprehensive medical infor-
mation from the VA’s computerized medical record system 
than would likely be available for a nonveteran population. 
This study was a retrospective review of information ob-
tained for the clinical treatment of infections, and there-
fore many SSTIs were not cultured. Although the increased 
frequency of culturing may have led to some increase in 
MRSA, the fact that the proportion of SSTIs that were 
MSSA stayed the same suggests that the increase in MRSA 
infections is real.
In conclusion, we showed an increase in CA-MRSA 
infections of the USA300 clone and an increase in SSTIs 
during a 5-year period in the ECS and systemwide at the 
VAMHCS. The emergence of the USA300 clone has led 
to not only to an increase in CA-MRSA infections but also 
an overall increase in SSTIs in our patient population. This 
ﬁ  nding suggests that this clone is becoming more virulent 
with a greater propensity to cause SSTIs.
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